​

ARS Pharmaceuticals Ownership | Who Owns ARS Pharmaceuticals?

OverviewForecastRevenueFinancialsChartTranscripts

ARS Pharmaceuticals Ownership Summary

ARS Pharmaceuticals is owned by 85.92% institutional investors, 16.83% insiders. Ra capital management is the largest institutional shareholder, holding 11.04% of SPRY shares. Vanguard US Total Market Shares ETF is the top mutual fund, with 1.90% of its assets in ARS Pharmaceuticals shares.

SPRY Ownership Benchmark

TypeName% Inst% Insiders% Retail
StockARS Pharmaceuticals85.92%16.83%-2.75%
SectorHealthcare Stocks 486.50%11.08%-397.59%
IndustryBiotech Stocks 304.14%11.08%-215.23%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Ra capital management10.86M11.04%$189.52M
Deerfield management company, l.p. (series c)9.72M9.89%$169.69M
Orbimed advisors8.29M8.43%$144.63M
Blackrock funding, inc. /de4.42M4.50%$77.19M
Sr one capital management, lp4.01M4.14%$42.34M
Alliancebernstein3.88M4.00%$40.94M
Vanguard group3.46M3.57%$36.56M
Franklin resources1.98M2.04%$20.85M
Adage capital partners gp1.73M1.76%$30.15M
Southpoint capital advisors lp1.71M1.74%$29.82M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Sr one capital management, lp4.01M10.32%$42.34M
Bioimpact capital1.30M3.94%$22.74M
Orbimed advisors8.29M3.62%$144.63M
Ra capital management10.86M3.19%$189.52M
Deerfield management company, l.p. (series c)9.72M3.08%$169.69M
Lisanti capital growth420.07K2.03%$7.33M
Wexford capital lp382.56K1.86%$6.68M
Nextech invest936.73K1.60%$9.88M
Cormorant asset management, lp1.10M1.43%$19.20M
First turn management593.29K1.12%$6.26M

Top Buyers

HolderShares% AssetsChange
Alliancebernstein3.88M0.01%3.81M
Adage capital partners gp1.73M0.05%1.73M
Southpoint capital advisors lp1.71M0.75%1.71M
Ubs group1.01M0.00%902.82K
Next century growth investors622.82K0.84%622.82K

Top Sellers

HolderShares% AssetsChange
Levin capital strategies289.15K0.49%-875.45K
Franklin resources1.98M0.01%-860.84K
Deerfield management company, l.p. (series c)9.72M3.08%-790.15K
Duquesne family office---536.90K
Cormorant asset management, lp1.10M1.43%-500.00K

New Positions

HolderShares% AssetsChangeValue
Adage capital partners gp1.73M0.05%1.73M$30.15M
Southpoint capital advisors lp1.71M0.75%1.71M$29.82M
Next century growth investors622.82K0.84%622.82K$10.87M
Driehaus capital management464.03K0.06%464.03K$8.10M
Bank of montreal /can/340.59K0.00%340.59K$3.59M

Sold Out

HolderChange
National bank of canada /fi/-1.00
Srs capital advisors-22.00
Stephens consulting-30.00
Capital performance advisors llp-33.00
Parallel advisors-38.00

Institutional Ownership Trends

DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Jun 30, 20251921.59%84,508,65610.87%851.42%11112.12%46-16.36%
Mar 31, 20251888.05%76,205,3346.92%771.44%992.06%5420.00%
Dec 31, 20241641.23%68,247,8906.54%701.61%88-14.56%4469.23%
Sep 30, 202416235.00%64,056,6692.41%661.58%10351.47%268.33%
Jun 30, 20241201.69%62,551,0554.44%641.68%683.03%24-4.00%

Top Mutual Funds Shareholders

HolderShares% HoldingChange
Vanguard US Total Market Shares ETF1.86M1.90%-
Vanguard Total Stock Mkt Idx Inv1.75M1.78%-38.90K
iShares Russell 2000 ETF1.30M1.32%-24.68K
AB Small Cap Growth A1.11M1.13%-16.04K
Franklin Biotechnology Discv A(acc)USD1.05M1.06%-
SPDR® S&P Biotech ETF979.69K1.00%24.20K
Fidelity Select Biotechnology944.16K0.96%-
MEDICAL BioHealth EUR Acc814.27K0.83%-
AB Discovery Growth A781.14K0.80%-9.44K
abrdn Healthcare Opportunities670.31K0.68%-

Recent Insider Transactions

DateNameRoleActivityValue
Aug 21, 2025Lowenthal Richard E PRESIDENT AND CEOSell$724.35K
Aug 21, 2025Scott Kathleen D. Chief Financial OfficerSell$187.50K
Aug 20, 2025Tanimoto Sarina CHIEF MEDICAL OFFICERSell$530.63K
Aug 19, 2025Tanimoto Sarina CHIEF MEDICAL OFFICERSell$173.13K
Jul 01, 2025Karas Eric Chief Commercial OfficerSell$254.86K

Insider Transactions Trends

DateBuySell
2025 Q3-5
2025 Q2-6
2025 Q1-5
2024 Q4-58
2024 Q3-51

SPRY Ownership FAQ

Who Owns ARS Pharmaceuticals?

ARS Pharmaceuticals shareholders are primarily institutional investors at 85.92%, followed by 16.83% insiders and -2.75% retail investors. The average institutional ownership in ARS Pharmaceuticals's industry, Biotech Stocks , is 304.14%, which ARS Pharmaceuticals falls below.

Who owns the most shares of ARS Pharmaceuticals?

ARS Pharmaceuticals’s largest shareholders are Ra capital management (10.86M shares, 11.04%), Deerfield management company, l.p. (series c) (9.72M shares, 9.89%), and Orbimed advisors (8.29M shares, 8.43%). Together, they hold 29.36% of ARS Pharmaceuticals’s total shares outstanding.

Does Blackrock own ARS Pharmaceuticals?

BlackRock is not among the top 10 institutional shareholders of ARS Pharmaceuticals.

Who is ARS Pharmaceuticals’s biggest shareholder by percentage of total assets invested?

Sr one capital management, lp is ARS Pharmaceuticals’s biggest shareholder by percentage of total assets invested, with 10.32% of its assets in 4.01M ARS Pharmaceuticals shares, valued at 42.34M$.

Who is the top mutual fund holder of ARS Pharmaceuticals shares?

Vanguard US Total Market Shares ETF is the top mutual fund holder of ARS Pharmaceuticals shares, with 1.90% of its total shares outstanding invested in 1.86M ARS Pharmaceuticals shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools